BMO Capital Markets Reiterates $41.00 Price Target for Nightstar Therapeutics (NITE)
BMO Capital Markets set a $41.00 price target on Nightstar Therapeutics (NASDAQ:NITE) in a research report report published on Monday, The Fly reports. The brokerage currently has a buy rating on the stock.
NITE has been the subject of several other research reports. UBS Group lowered shares of Nightstar Therapeutics from an outperform rating to a market perform rating in a research note on Wednesday, June 27th. Mizuho reissued a buy rating and set a $20.00 price target on shares of Nightstar Therapeutics in a research report on Tuesday, August 14th. Zacks Investment Research raised shares of Nightstar Therapeutics from a sell rating to a hold rating in a research report on Thursday, August 9th. Leerink Swann increased their price target on shares of Nightstar Therapeutics from $30.00 to $35.00 and gave the stock a positive rating in a research report on Monday. Finally, Janney Montgomery Scott initiated coverage on shares of Nightstar Therapeutics in a research report on Wednesday, August 22nd. They set a buy rating and a $34.00 price target on the stock. Three investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Nightstar Therapeutics has an average rating of Buy and a consensus target price of $32.86.
Shares of NITE stock opened at $19.00 on Monday. Nightstar Therapeutics has a 1-year low of $10.01 and a 1-year high of $29.55.
Several institutional investors and hedge funds have recently modified their holdings of NITE. Bank of America Corp DE acquired a new stake in shares of Nightstar Therapeutics during the second quarter worth about $132,000. Stanley Laman Group Ltd. acquired a new stake in shares of Nightstar Therapeutics during the second quarter worth about $195,000. Millennium Management LLC acquired a new stake in shares of Nightstar Therapeutics during the first quarter worth about $507,000. Woodford Investment Management Ltd acquired a new stake in shares of Nightstar Therapeutics during the second quarter worth about $5,024,000. Finally, Partner Fund Management L.P. lifted its position in shares of Nightstar Therapeutics by 0.7% during the second quarter. Partner Fund Management L.P. now owns 1,016,980 shares of the company’s stock worth $16,272,000 after purchasing an additional 7,007 shares in the last quarter. 28.62% of the stock is currently owned by institutional investors and hedge funds.
About Nightstar Therapeutics
Nightstar Therapeutics PLC is a clinical-stage gene therapy company, which engages in the development and commercialization of novel one-time treatments for patients suffering from rare inherited retinal diseases. Its pipeline includes NSR-REP1, for the treatment of choroideremia; NSR-RPGR, for the treatment of X-linked retinitis pigmentosa; and NSR-BEST1, for the treatment of vitelliform macular dystrophy.
Further Reading: Terms to Better Understand Call Options
Receive News & Ratings for Nightstar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nightstar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.